Excisanin A suppresses proliferation by inhibiting hypoxia-inducible factor-1α expression in human hepatocellular carcinoma cells

Li Zhuo Han¹, Changgao Jiang²*, Chunliu Mi³, Ke Si Wang⁴, Hong Xiang Zuo¹, Zhe Wang¹, Ming Yue Li¹, Zhi Hong Zhang¹, Xuejun Jin¹

¹Key Laboratory of Natural Resources of Changbai Mountain & Functional Molecules, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji 133002. ²Department of Gastroenterology, Affiliated Hospital of Yanbian University, Yanji 133000, Jilin Province, ³International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, School of Basic Medicine, Xinxiang Medical University, Xinxiang, 453003, Henan, ⁴Medical College of Dalian University, Dalian 116622, Liaoning Province, China

*For correspondence: Email: jch2011@163.com; Tel/Fax: +86-433-2660355

Sent for review: 12 April 2020 Revised accepted: 15 November 2020

Abstract

Purpose: To investigate the effect of excisanin A on human hepatocellular carcinoma cells as well as to elucidate its mechanism of action.

Methods: Molecular docking was used to determine the binding characteristics of excisanin A to HIF-1α protein. The transcriptional activation and viability of excisanin A were assessed using Luciferase reporter and MTT assay. The HIF-1α protein in the nucleus was assayed using western blot and immunofluorescence. HIF-1α and VEGF mRNA levels were evaluated using reverse-transcription polymerase chain reaction (RT-PCR). Cell proliferation was determined by flow cytometry, as well as by EdU and clonogenic assays. In vivo tumor growth was assessed in a murine xenograft model of SK-Hep1 cells.

Results: Excisanin A inhibited HIF-1α transcriptional activation, as well as HIF-1α protein synthesis (p < 0.001). Excisanin A also reduced VEGF protein and mRNA expressions (p < 0.001). In addition, the compound inhibited the proliferation of hepatocellular carcinoma cells, and tumor growth in the xenograft tumor model.

Conclusion: Excisanin A is a potent HIF-1α inhibitor, supporting its potential development for human hepatoma therapy.

Keywords: Excisanin A, HIF-1α, Protein synthesis, Hepatoma therapy

INTRODUCTION

When oxygen levels are very low, HIF-1α transfers to the nucleus. Then, HIF-1α and HIF-1β begin the transcriptional program [4]. HIF-1α levels are closely related to VEGF expression involved in tumor angiogenesis and proliferation index [5]. As HIF-1α could promote tumor angiogenesis and growth, targeting HIF-1α may be a critical drug for cancer treatment. Many
types of *Isodon* (Labiatae), a species of plant widely distributed throughout China, exhibit anti-inflammatory and anti-bacterial activities. *Isodon* diterpenoids have been identified to possess intense antitumor activity and very low toxicity, thus receiving considerable attention from both phytochemical and biological fields [6]. In this research, we discovered that excisanon A inhibited HIF-1α protein. Moreover, excisanon A suppressed the HIF-1α downstream genes such as VEGF, which is very important for tumor growth. Excisanon A also inhibited tumor cell proliferation. Based on these results, we further demonstrated that in vivo, excisanon A showed significant antitumor activity, which elicited no apparent toxicity in experimental animals.

**EXPERIMENTAL**

**Cell lines and chemicals**

Hep3B and SK-Hep1 cells (ATCC, USA) were routinely cultured in DMEM including 10% FBS and 1% penicillin/streptomycin. The hypoxic was kept in atmosphere at 1% O2, 5% CO2 and 37°C. Dimethyl sulfoxide, cycloheximide and MG132 were purchased from Sigma-Aldrich. Excisanon A (≥ 98%) was extracted from *Isodon Macrocalyxin D*, and the structure of excisanon A is displayed in Figure 1 A.

**Molecular docking**

Molecular docking study was performed to detect the binding mode between excisanon A to HIF-1α protein using Autodock vina 1.1.2. The search grid of the HIF-1α was identified as center_x: -113.125, center_y: -55.376, and center_z: 12.189 with dimensions size_x: 15, size_y: 15, and size_z: 15.

**Luciferase reporter assay**

pGL3-HRE-Luciferase plasmid and pRL-CMV were co-transfected into SK-Hep1 cells. Then, cells were incubated with Excisanon A and under hypoxia for 12 h. Determined luciferase activity with a luciferase assay kit (Promega, USA).

**MTT assay**

After cells adhered, they were treated with excisanon A for 24 h. Then, living cells changed MITT (Sigma-Aldrich) to formazan, which dissolved in DMSO, producing blue-purple color.

**Western blotting**

Cell lysates were prepared as described previously [5]. The primary antibodies were HIF-1α (Novus Biologicals, USA), phospho-p70S6K, Cyclin D1, phospho-ERK1/2, phospho-Akt, phospho-mTOR, phospho-eIF4E, phospho-SAPK/JNK (Cell Signaling Technology), Topo-I, VEGF (Santa Cruz, USA), α-tubulin (Sigma-Aldrich, USA) and c-Myc (Abmart, Shanghai, China). Finally, the appropriate secondary antibody was detected by enhanced chemiluminescence.

**Immunofluorescence assay**

Immunofluorescence assay was performed as described previously. Briefly, the cell nuclei were labeled with DAPI. The HIF-1α proteins appeared green and the nuclei appeared blue under confocal microscopy (Nikon, Japan) [6].

**Reverse transcription-PCR (RT-PCR) analysis**

SK-Hep1 cells treated with Excisanon A and isolated total RNA according to the manufacturer’s instructions (Invitrogen, USA). GAPDH served as a housekeeping gene control. The bands were visualized by 3% agarose gel under UV light and photographed.

**Flow cytometry analysis**

Cell cycle was detected by propidium iodide staining, as described previously [8].

**Clonogenic assay**

Cells treated with excisanon A. Two weeks later, Colonies were fixed with 10% formaldehyde and tinted with 1% crystal violet. The image was photographed with a camera.

**EdU assay**

Cells were plated in 96-well culture plates. Twenty-four hours later, cells were treated with excisanon A. Cells were incubated with EdU. Then, cells treated 1 × Apollo® reaction cocktail and the cell nucleus was tinted with Hoechst 33342.

**Tumor xenografts**

All mouse protocols were approved by the Yanbian University Institutional Animal Care and Use Committee. 1 × 10^7 cells in PBS were injected into the subcutaneous. Five days later, BALB/C nude mice (n = 5/group, five-week, male, Vital River, China) were given excisanon A three times per week. The body weight and tumor was measured with a caliper for 40 days and it was calculated following equation: (length × (width)^2)/2.
Immunohistochemical analysis

The paraffin-embedded sections of the tumor tissue were prepared for H&E staining and immunohistostaining. Histopathological changes and positive stained area was photographed by a photo microscope [2,9].

Statistics

Data are expressed as mean ± SD, and were compared using one-way ANOVA and Tukey’s multiple comparison tests with the aid of SPSS software. $P < 0.05$ was considered statistically significant.

RESULTS

Excisanin A was identified as a HIF-1 inhibitor

We performed HIF-1α reporter assays, and found excisanin A suppressed hypoxia-induced reporter gene expression in a concentration-dependent manner (Figure 1 B). Additionally, viability at concentrations 3-30 μM of excisanin A after 24 h of treatment showed no obvious changes in Hep3B and SK-Hep1 cells, suggesting that the effects of excisanin A are not the result of cytotoxicity (Figure 1 C). Subsequently, Molecular docking assays revealed that excisanin A is properly bound to HIF-1α (Figure 2 A and B).

Excisanin A decreases HIF-1α protein levels

In Hep3B and SK-Hep1 cells, excisanin A significantly inhibited HIF-1α expression in a concentration-dependent manner in 1% O2 (Figure 3 A). And, excisanin A inhibited the accumulation of HIF-1α at each time point in 1% O2 (Figure 3 B). Next, immunofluorescence staining was performed. In Hep3B and SK-Hep1 cells, excisanin A (30 μM) nearly totally suppressed hypoxia-induced HIF-1α protein in the nucleus after 12 h of treatment (Figure 3 C).

Excisanin A inhibits HIF-1α protein synthesis

Excisanin A decreased HIF-1α protein levels in the presence of proteasome inhibitor (MG-132) (lanes 3 and 5 in Figure 4 A). The results indicated that excisanin A significantly inhibits HIF-1α protein synthesis. The use of the cycloheximide (CHX) inhibits protein synthesis. As displayed in Figure 4 B, while HIF-1α levels declined promptly in CHX treatment, excisanin A did not affect the HIF-1α degradation rate. Thus, excisanin A does not facilitate HIF-1α degradation. HIF-1α mRNA level was not altered with Excisanin A treatment in Hep3B and SK-Hep1 cells (Figure 5 A and 5 B). These findings suggested that excisanin A inhibited HIF-1α protein expression but did not inhibited HIF-1α mRNA expression.
Excisanin A decreases HIF-1α protein levels. (A) Cells were incubated with excisanin A and incubated in hypoxia for 12 h. Western blot assay was performed. (B) HIF-1α expression was analyzed by immunoblotting. (C) HIF-1α distribution was detected by immunofluorescence in cells. The location and size of the nucleus were stained with DAPI. magnification = 400×

Figure 3

Excisanin A inhibits HIF-1α protein synthesis. (A) Cells treated with MG-132 (10 μM) for 30 min before adding excisanin A (30 μM). After 12 h, protein was analyzed by immunoblotting. *** p < 0.001 vs hypoxia group, n=3. (B) Cells were cultivated in 1 % O₂ atmosphere. After 4 h, CHX (10 μM) and excisanin A were added in culture media. After the addition of CHX for 15, 30, or 45 min, HIF-1α protein was analyzed by immunoblotting

Figure 4

Excisanin A decreases HIF-1α target genes expression

Excisanin A inhibited VEGF mRNA and protein level in Hep3B and SK-Hep1 cells (Figure 5 A and B).

Figure 5

Excisanin A inhibits cell cycle progression in the G1 phase

Hep3B cells were treated with excisanin A resulted in an increase of G1 phase cells from 56.28 to 61.14, 67.65, and 71.84 % in the concentrations of 5, 10, and 30 μM excisanin A. Similarly, treatment of SK-Hep1 with excisanin A also increases the number of G1-phase cells (Figure 6). In Figure 7, excisanin A inhibited cyclin D1 and c-Myc expression, thereby blocking cell cycle at the G1 phase.

Excisanin A inhibits the proliferation

EdU assay confirmed that excisanin A suppressed EdU-positive cells number, indicating that excisanin A suppressed Hep3B and SK-Hep1 cells proliferation in vitro (Figure 8 A). Clonogenicity of cells in excisanin A-treated groups were decreased with increasing concentration (Figure 8 B). Furthermore, MTT assay showed that excisanin A inhibits cell proliferation in both normoxia and hypoxic conditions (Figure 9 C and D).

Excisanin A inhibits tumor growth in a xenograft tumor model

As shown in Figure 10 A, excisanin A inhibits growth of hepatocellular carcinoma, while mice body weight was unchanged (Figure 10 B). After the last treatment, the tumor was harvested, and the representative tumor block was displayed in Figure 10 C. Consistent with above findings, excisanin A decreased HIF-1α protein in tumors (Figure 10 D).
Excisanin A inhibited the HIF-1α and VEGF expression in tumor (Figure 10 E). Taken together, our experiment confirmed that HIF-1α downregulation by excisanin A contributed to inhibit tumor growth and angiogenesis in tumor tissues.

Figure 6: Excisanin A blocks cell cycle progression. Cells were cultured in 1% O₂ for 12 h and treated with different concentrations of excisanin A (A and B). Cycle progression was analyzed by flow cytometry. (B) Immunoblot showed protein expression. (significant at* p <0.05, ** p < 0.01, *** p < 0.001, n = 3)

Figure 7: Excisanin A blocks cyclin D1 and c-Myc expression

Figure 8: Excisanin A regulates the proliferation. (A) Treated cells with 30 μM excisanin A in normoxia for 12 h. Cells were observed by immunofluorescence staining. (B) The image was collected by the camera.

Figure 9: Excisanin A regulates the proliferation by MTT analysis; * p < 0.05, ** p < 0.01, *** p < 0.01 significant with respect to the normoxia control; # p < 0.05, ## p < 0.01, ### p < 0.01 significant with respect to the hypoxia control
Figure 10: Excisanin A inhibits growth and tumorigenicity of hepatocellular carcinoma. (A) Tumor volume and (B) body weight was determined. (C) Photographs of mice bearing subcutaneously implanted tumor. (D) Immunoblots showed protein expression of HIF-1α. * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \) vs control group, \( n=5 \). (E) HE staining and immunohistostaining. Original magnification, 200×

Effect of excisanin A effects mTOR/p70S6K/4E-BP1 and MAPK pathways

Literatures have shown that PI3K-Akt-mTOR and MAPK mediate the translation of Hypoxia-inducible Factor 1α [10, 11]. Unfortunately, we found that excisanin A only inhibits phosphorylation of mTOR, whereas it promotes phosphorylation of Akt, p70S6K, eIF4E, JNK and ERK in Hep3B cells (Figure 11). It is a problem awaiting further study to determine the pathway by which excisanin A inhibits HIF-1α synthesis.

Figure 11: Excisanin A affects mTOR/p70S6K/4E-BP1 and MAPK pathways. * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \) vs hypoxia group, \( n=3 \)

DISCUSSION

Hypoxic conditions induce activation of the HIF-1α sub-unit, an important transcription factor for adaptation to hypoxic conditions within the tumor microenvironment. Thus, the development of HIF-1α inhibitors in cancer treatment is a huge challenge. In the process of trying to find anticancer agents from natural products, excisanin A, a natural ent-kaurene diterpenoid, was isolated from the traditional Chinese medicine *Isodon Macrocalyxin*D. Here, we found that excisanin A suppressed HIF-1α protein synthesis.

VEGF, a downstream target of HIF-1α, exerts multiple effects on tumor angiogenesis, including stimulating new blood and lymphatic vessel formation and increasing vascular permeability [12-16]. VEGF promotes the delivery of peripheral oxygen via stimulating angiogenesis, which involves the migration, proliferation and differentiation of the endothelial cell and the proteolysis of extracellular matrix. As expected, excisanin A decreased VEGF mRNA and protein levels.

We found that Excisanin A reduces cell proliferation by arresting the cell cycle and inhibits cyclin D1 and c-Myc protein level. Moreover, Figure 6C and 6D showed that the effects of excisanin A on cell proliferation are consistent in normoxia or hypoxic conditions. We examined HIF-1α and VEGF expression in the sections of tumor and found that excisanin A suppressed their expression in tumor tissues.

CONCLUSION

The findings of this study demonstrate that excisanin A suppresses HIF-1α protein synthesis in Hep3B and SK-Hep1 cells. Furthermore, excisanin A suppresses cancer cell proliferation by arresting cell cycle at the G1 phase. This mechanism may partly explain the anti-tumor mechanism of excisanin A, thus supporting its development as an anticancer drug.

DECLARATIONS

Acknowledgement

This work was partially supported by National Natural Science Foundation of China, no. 81360496. This work was partially supported by Jilin Province Science and Technology Development Plan item (no. 2030101229JC) and Project of Education Department of Jilin Province (no. 2016.281). This study also received assistance from Yanbian University Youth Research Fund Project (2017.no. 31).

Conflict of interest

No conflict of interest to disclose with regard to this work.
**Contribution of authors**

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Xuejun Jin and Changgao Jiang conceived and designed the study. Li Zhuo Han, Chunliu Mi and Ke Si Wang performed all the experiments and wrote. Hong Xiang Zuo and Zhe Wang prepared all the figures. Ming Yue Li, Zhi Hong Zhang, Xuejun Jin reviewed and edited the manuscript. Li Zhuo Han, Chunliu Mi and Ke Si Wang equally contributed to this work. All authors read and approved the manuscript.

**Open Access**

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/redirect), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

**REFERENCES**

1. Yang T, Yao Q, Cao F, Liu Q, Liu B, Wang XH. Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and anti-angiogenesis. Int J Nanomed 2016; 11: 6679-6692.

2. Mi C, Ma J, Wang KS, Zuo HK, Wang Z, Li MY, Piao LX, Xu GH, Li X, Quan ZS, Jin X. Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1alpha via the mTOR/p70S6K/4E-BP1 and MAPK pathways. J Ethnopharmacol 2017; 203: 27-38.

3. Li MY, Mi C, Wang KS, Wang Z, Zuo HK, Piao LX, Xu GH, Li X, Ma J and Jin X. Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1alpha signaling. Chem Biol Interact 2017; 274: 58-67.

4. Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M, Cavo M. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. Transl Res 2015; 165(6): 641-650.

5. Deniz H, Karakok M, Yagci F, Guldur ME. Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol 2010; 42(1): 103-107.

6. Ohsaki A, Ozawa M, Komiyama K, Kishida A, Isobe T. The cytotoxic activity of diterpenoids from Isodon species. Nat Prod Commun 2012; 7(8): 977-978.

7. Zhang ZH, Mi C, Wang KS, Wang Z, Li MY, Zuo HK, Xu GH, Li X, Piao LX, Ma J, Jin X. Cheilidonine inhibits TNF-alpha-induced inflammation by suppressing the NF-kappaB pathways in HCT116 cells. Phytother res 2018; 32(1): 65-75.

8. Mi C, Ma J, Wang KS, Zuo HK, Wang Z, Li MY, Piao LX, Xu GH, Li X, Quan ZS, Jin X. Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1alpha via the mTOR/p70S6K/4E-BP1 and MAPK pathways. J Ethnopharmacol 2017; 203: 27-38.

9. Li J, Ma J, Wang KS, Mi C, Wang Z, Piao LX, Xu GH, Li X, Lee JJ, Jin X. Baicalein inhibits TNF-alpha-induced NF-kappaB activation and expression of NF-kappaB-regulated target gene products. Oncol reports 2016; 36(5): 2771-2776.

10. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277(41): 38205-38211.

11. Zhong H, Chiles K, Feldser D, Launghner E, Hanrahnn C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60(6): 1541-1545.

12. Berra E, Benizi E, Gionoves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22(16): 4082-4090.

13. Semenza GL. Life with oxygen. Sci 2007; 318(5847): 62-64.

14. Ferrari N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-676.

15. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312(5): 549-560.

16. Bluff JE, Menakuru SR, Cross SS, Higham SE, Balasubramaniam SP, Brown NJ, Reed MW, Staton CA. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer 2009; 101(4): 666-672.